Features

Cell and gene therapies are a niche segment in the global bio/pharmaceutical market. What are leading products, and what are key developments thus far in 2025? 

A recent PwC analysis examined the impact of productivity, wages, and overall value in industries with strong and limited exposure to AI. What did it find?

The blockbuster success of Novo Nordisk’s Ozempic/Wegovy and Lilly’s Mounjaro/Zepbound, all injectables, have put GLP-1/GIP agonists on the map, but will new oral drugs be a game-changer?

Congress is moving forward with proposed legislation to increase both new and reshored pharma manufacturing in the US. What measures are being considered, and where do they stand?

Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. Which companies are expanding, and who is leading the charge?

The industry has weighed in on the US government’s potential plan to impose tariffs specific to the pharmaceutical industry. Where does the initiative stand, and what is the industry saying?

Capital flow in the biotech sector has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn?

New modalities, ADCs and bispecific antibodies, accounted for $18 billion in cancer medicine spending in 2024 and are fast-growing on a pipeline basis. What else stands out in the oncology drug market?

In times of supply-chain uncertainty, a new DCAT Research & Benchmarking report addresses a key question in the pharma customer–supplier relationship: What does it take to become a “Customer of…

Antibody drug conjugates (ADCs) have been a strong niche in the global oncology drug market. What are the leading commercial ADCs and key pipeline contenders, and will ADCs continue to bode well for CDMOs/CMOs? A look at what lies ahead.